Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF).

2.1 The Primary Aim WARCEF is a two-arm (1:1) double-blind randomized multicenter clinical trial. Its primary aim is to compare the effectiveness of warfarin and aspirin therapies in heart failure patients. while taking account of risk of hemorrhage. The primary null hypothesis is that in patients with EF s 35%, there is no difference between warfarin (INR 2.5-3.0 with a target INR of 2.75) and aspirin (325 mg/day) therapies in time to the first to occur of ischemic stroke, intracerebral hemorrhage (ICH). or death. This is tested against the a.lternative hypothesis of a non-zero difference between these two therapies, at